Ewing's sarcoma and primitive neuroectodermal family of tumors

被引:119
作者
Carvajal, R
Meyers, P
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
关键词
D O I
10.1016/j.hoc.2005.03.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ewing's sarcoma (ES) initially was believed to be of perivascular endothelial origin. The Ewing's sarcoma family of tumors (EFT) includes ES of bone (ESB), extraosseous ES (EES), peripheral primitive neuroectodermal tumor of bone (pPNET), and malignant small-cell tumor of the thoracopulmonary region, or Askin's tumor, all of which are now known to be neoplasms of neuroectodermal origin. The degree of neuronal differentiation has been used for histopathologic subclassification of the EFT as classical ES (ESB or EES), which is characterized by minimal evidence of neural differentiation, and pPNET, which displays evidence of neural differentiation by standard microscopy, electron microscopy, or immunohistochemistry. Because the behavior, prognosis, and treatment appear to be similar for all subsets of EFT, this histopathologic subclassification may not be clinically significant, though some debate remains whether neural differentiation predicts for inferior outcome.
引用
收藏
页码:501 / +
页数:27
相关论文
共 197 条
[1]   Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: Correlation with clinical outcome [J].
Amir, G ;
Issakov, J ;
Meller, I ;
Sucher, E ;
Peyser, A ;
Cohen, IJ ;
Yaniv, I ;
Ben Arush, MW ;
Tavori, U ;
Kollender, Y ;
Ron, N ;
Peylan-Ramu, N .
HUMAN PATHOLOGY, 2002, 33 (02) :170-174
[2]   RESPONSE TO IFOSFAMIDE AND MESNA - 124 PREVIOUSLY TREATED PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA [J].
ANTMAN, KH ;
RYAN, L ;
ELIAS, A ;
SHERMAN, D ;
GRIER, HE .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :126-131
[3]   High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma [J].
Atra, A ;
Whelan, JS ;
Calvagna, V ;
Shankar, AG ;
Ashley, S ;
Shepherd, V ;
Souhami, RL ;
Pinkerton, CR .
BONE MARROW TRANSPLANTATION, 1997, 20 (10) :843-846
[4]  
AURIAS A, 1983, NEW ENGL J MED, V309, P496
[5]   Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma [J].
Bacci, G ;
Picci, P ;
Mercuri, M ;
Ferrari, S ;
Longhi, A ;
Cesari, M ;
Rosito, P ;
Mancini, AF ;
Barbieri, E ;
Baldini, N .
ACTA ONCOLOGICA, 1998, 37 (7-8) :671-676
[6]  
Bacci G, 1998, CANCER-AM CANCER SOC, V82, P1174, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1174::AID-CNCR24>3.0.CO
[7]  
2-2
[8]  
BACCI G, 1989, CANCER-AM CANCER SOC, V63, P1477, DOI 10.1002/1097-0142(19890415)63:8<1477::AID-CNCR2820630805>3.0.CO
[9]  
2-8
[10]   Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute [J].
Bacci, G ;
Mercuri, M ;
Longhi, A ;
Bertoni, F ;
Barbieri, E ;
Donati, D ;
Giacomini, S ;
Bacchini, P ;
Pignotti, E ;
Forni, C ;
Ferrari, S .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (17) :2243-2251